TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18447762
Drug: Active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intervention by drug consultation center (DCC) - information by phone, mailed written form, and text messages
Study: 16487434
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg p.o. daily at bedtime)
Study: 9361332
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg haloperidol (i.v.)
Study: 9361332
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg haloperidol (i.v.)
Study: 22205309
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (RW) with 30 g alcohol/d
Study: 22205309
Drug: Gin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gin with 30 g alcohol/d
Study: 18176337
Drug: Dexmethylphenidate extended-release
Normalized name: dexmethylphenidate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmethylphenidate extended-release (D-MPH-ER) 20 mg/day
Study: 7564470
Drug: Busulfan plus
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan plus continuous oral vitamin A
Study: 1948817
Drug: Protamine chloride
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine chloride 80 mg
Study: 1948817
Drug: Protamine chloride
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine chloride 100 mg
Study: 1948817
Drug: Protamine chloride
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine chloride 20-100 mg
Study: 1948817
Drug: Protamine chloride
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine chloride 60-100 mg
Study: 6119712
Drug: Neuroleptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic therapy with constant doses of butyrophenones
Study: 27636018
Drug: Kisspeptin-10 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin-10 (4 μg/kg/h) infusion
Study: 27636018
Drug: NK3R antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK3R antagonist AZD4901 40 mg twice daily orally
Study: 27636018
Drug: NK3R antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK3R antagonist AZD4901
Study: 22307881
Drug: Veterans Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans Health Administration Vocational Rehabilitation Program (VRP)
Study: 17940786
Drug: Submucosal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal infiltration with 2 mg/kg tramadol in 3 ml of normal saline (1.5 ml per tonsil)
Study: 15965309
Drug: Entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone 200 mg administered 4 times during the day with controlled-release levodopa/carbidopa 100 mg/25 mg (Sinemet CR)
Study: 12798612
Drug: MDCK cell
Normalized name: influenza virus vac qv 22-23 (6 mos up) MDCK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCK cell grown influenza vaccine
Study: 12798612
Drug: Egg-derived influenza
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-derived influenza vaccine
Study: 10822319
Drug: Perindopril 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4-8 mg/daily
Study: 1513922
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 to 3.5 mg/day)
Study: 6381081
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (postural drainage and periodic application of a face mask with positive expiratory pressure)
Study: 6381081
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (PEP in the sitting position)
Study: 6381081
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (postural drainage, percussion and vibration)
Study: 6381081
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment D (forced expiration technique in the sitting position)
Study: 27049053
Drug: Trial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial preparation (2 × 250 mg)
Study: 27049053
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (2 × 250 mg)
Study: 27049053
Drug: Trial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial preparation and Reference preparation
Study: 23091148
Drug: AL (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL (25 mg of allopurinol/kg of body mass)
Study: 23091148
Drug: UAF (AL
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAF (AL plus 6.25 g of UA sodium salt/kg of feed)
Study: 23091148
Drug: UAI (AL
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAI (AL plus 120 mg of UA sodium salt injected daily)
Study: 23091148
Drug: INOAL (INO
Approvals — FDA: no, EMA: no, PMDA: no
Description: INOAL (INO plus 50 mg of allopurinol/kg of body mass)
Study: 19605567
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of sucrose (37.5 g) 2 h after breakfast and lunch
Study: 19605567
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of sucrose (75 g, equivalent to 2 cans of a soft drink)
Study: 8931684
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate 0.6 mg/kg
Study: 1563056
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (2 ml, 8 mg)
Study: 1563056
Drug: Hyperbaric tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric tetracaine (2 ml, 8 mg)
Study: 3910157
Drug: High-dose fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fractionated pre-operative irradiation (25.5 Gy in 5-7 days)
Study: 10847307
Drug: Other antipsychotic
Normalized name: Other antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antipsychotic drugs (Control)
Study: 8838441
Drug: 311C90 (1-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 311C90 (1-50 mg, single oral doses)
Study: 1289588
Drug: Cefprozil (CFPZ)
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil (CFPZ) at a mean dose of 8.4 mg/kg, administered 3-4 times daily for an average of 6 days.
Study: 1289588
Drug: Cefprozil (CFPZ)
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil (CFPZ) at a daily dose of 30.1-45.0 mg/kg.
Study: 1289588
Drug: Cefprozil (CFPZ)
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil (CFPZ) compared to other antibiotics (CEX, CCL, ABPC, DMPPC, MCIPC).
Study: 3885985
Drug: Bepridil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (400 mg/day for 10 weeks)
Study: 20121112
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 1)
Study: 20121112
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 2)
Study: 20121112
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m² and cetuximab with extended field radiation therapy (EFRT) (DL 1)
Study: 20473913
Drug: Catumaxomab (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catumaxomab (10, 20, 50 and 150 mug i.p. infusion on Days 0, 3, 7 and 10)
Study: 3792435
Drug: Aspirin 5
Normalized name: aspirin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 5 mg/kg
Study: 3792435
Drug: Aspirin 10
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 10 mg/kg
Study: 12365879
Drug: Specific preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific preventive intervention (low-dose risperidone therapy, mean dosage 1.3 mg/d, and cognitive behavior therapy)
Study: 29938452
Drug: UI05MSP015CT (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UI05MSP015CT (15 mg once a day)
Study: 29938452
Drug: Mosapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (5 mg three times a day, control group)
Study: 26360545
Drug: Computerized Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized Cognitive Behavioral Therapy (CCBT)
Study: 24577019
Drug: IV dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dexmedetomidine (0.2 μg/kg/h titrated to 0.7 μg/kg/h)
Study: 10362386
Drug: Flurbiprofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (40 mg, two patches) administered 12 hours before exercise
Study: 10362386
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches administered 12 hours before exercise
Study: 28531791
Drug: Brioche group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brioche group (65 g brioche enriched in protein and energy, 12.8 g protein, 180 kcal)
Study: 28531791
Drug: Supplement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group (200-ml energy-dense liquid, 14 g protein, 200 kcal)
Study: 22464973
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 mg once-daily
Study: 22464973
Drug: JNJ-37822681 10
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 10 mg bid vs Olanzapine
Study: 11014413
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and caffeine
Study: 17628221
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and placebo
Study: 10942231
Drug: ATRA followed
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA followed by three courses of daunorubicin-AraC chemotherapy
Study: 1603224
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (9 g a day)
Study: 6141858
Drug: Almitrine 100
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 100 mg orally
Study: 26898748
Drug: Intensive Behavior
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Behavior Therapy fee-for-service (FFS) model
Study: 18622251
Drug: Lisinopril-based regimen
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril-based regimen (n = 13)
Study: 15913920
Drug: Desipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (up to 300 mg per day)
Study: 1095122
Drug: Nafoxidine (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafoxidine (reference compound)
Study: 22846643
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose acupuncture (additional 4 needles at non‐acupoints bilaterally)
Study: 22846643
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose acupuncture (one needle at point Hegu bilaterally)
Study: 22846643
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose acupuncture
Study: 22846643
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose acupuncture
Study: 9698663
Drug: Parenteral polyoestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral polyoestradiol phosphate (PEP) 240 mg/month (group 2, n = 227)
Study: 7137990
Drug: Aerosolized rimantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized rimantadine HCl 25 mg in saline (10 min exposure twice daily)
Study: 7137990
Drug: Oral rimantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rimantadine HCl 50 mg (every 6 h, three times daily)
Study: 7137990
Drug: Placebo (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (both aerosol and oral routes)
Study: 7137990
Drug: Aerosolized rimantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized rimantadine and oral rimantadine
Study: 28299764
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of furosemide (120 mg stat)
Study: 28299764
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of furosemide (4 mg/minute)
Study: 28299764
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection and infusion of furosemide
Study: 27219099
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg) administered before viewing images (encoding condition)
Study: 27219099
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg) administered immediately after viewing images (consolidation condition)
Study: 27219099
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered both before and after viewing images (control condition)
Study: 27219099
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg) in encoding condition with greater alcohol-induced stimulation
Study: 23723317
Drug: Rituximab retreatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab retreatment at 1000 mg×1 (Arm A)
Study: 23723317
Drug: Rituximab retreatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab retreatment at 1000 mg×2 (Arm B)
Study: 15650985
Drug: Oxycodone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.5 mg/kg/h
Study: 15650985
Drug: Oxycodone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 1.0 mg/kg/h
Study: 15650985
Drug: Oxycodone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.5 mg/kg/h and 1.0 mg/kg/h
Study: 11205921
Drug: TCR-zeta molecule
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCR-zeta molecule expression
Study: 2648188
Drug: 1.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g/kg protein diet
Study: 2648188
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg diet with protein evenly distributed between meals
Study: 2648188
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg diet with protein restricted to the evening meal
Study: 30794334
Drug: Budesonide with
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide with probiotic supplements (BP)
Study: 29029260
Drug: RSV postfusion
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV postfusion F protein vaccine (120 µg) with glucopyranosyl lipid adjuvant (5 µg)
Study: 29029260
Drug: RSV postfusion
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV postfusion F protein vaccine
Study: 25599284
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg plus optimized background regimen (OBR)
Study: 23568514
Drug: Standardized hypnotherapeutic‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized hypnotherapeutic‐behavioral treatment (n = 20)
Study: 15339772
Drug: Misoprostol (25-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (25-microg intravaginal dose)
Study: 10513186
Drug: LA with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA with 2 ml of 1% lidocaine using a 24‐gauge needle
Study: 10513186
Drug: LA with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA with 0.5 ml of 1% lidocaine using a 27‐gauge needle
Study: 8655712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nested PCR and immunohistochemistry
Study: 1517929
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy for 12 weeks
Study: 1517929
Drug: Placebo dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosing for 12 weeks
Study: 6391140
Drug: Thymosin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin treatment
Study: 27256936
Drug: Drug Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Adherence Enhancement Program
Study: 22031518
Drug: Standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose control through insulin sliding scale treatment
Study: 15733643
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment expectancy
Study: 15733643
Drug: Taking pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking pain medication and poor functional status at baseline
Study: 12660386
Drug: High-strength levorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-strength levorphanol (0.75 mg)
Study: 12660386
Drug: Low-strength levorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-strength levorphanol (0.15 mg)
Study: 10713745
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin concentration before eating the test meal
Study: 8661977
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin (sCT) (all doses)
Study: 1997698
Drug: Oral BCG
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCG
Study: 6581174
Drug: Tetracycline therapy
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline therapy (daily for 50 weeks)
Study: 28575910
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of colostrum (OAC)
Study: 22880805
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefazolin sodium intravenously 1 h prior to catheter insertion
Study: 18978105
Drug: 10-microgram E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-microgram E2 vaginal tablets
Study: 16085584
Drug: (99m)Tc‐tetrofosmin uptake
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc‐tetrofosmin uptake after nitrate administration
Study: 16085584
Drug: (99m)Tc‐tetrofosmin perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc‐tetrofosmin perfusion defect severity after nitrate administration
Study: 11910262
Drug: Paroxetine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine at 20 mg/day for 10 days
Study: 11910262
Drug: Sertraline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline at 50 mg/day for 3 days, followed by 100 mg/day for 10 days
Study: 11910262
Drug: Fluoxetine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine at 20 mg/day for 28 days
Study: 3529911
Drug: Flecainide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (up to 2 mg/kg intravenously and then orally)
Study: 3529911
Drug: Quinidine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (up to 1.2 g orally)
Study: 26664304
Drug: Atorvastatin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 160 mg loading dose followed by 80 mg daily
Study: 19903982
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg, 1 week)
Study: 3364403
Drug: Ca citrate
Normalized name: CALCIUM 200MG (CA CITRATE-950MG) TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca citrate (750 mg)
Study: 3364403
Drug: Ca(H2PO4)2 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(H2PO4)2 (750 mg)
Study: 25359444
Drug: Control (fifteen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fifteen 40‐minute sessions of transcutaneous electrical nerve stimulation, microwave treatment, and standardized exercises)
Study: 25359444
Drug: GDS‐G (eleven
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDS‐G (eleven 50‐minute group GDS sessions)
Study: 23771800
Drug: PM00104 (Zalypsis)
Normalized name: Zalypsis
DrugBank: Zalypsis (DB12454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM00104 (Zalypsis) administered as a 1-h, weekly, intravenous infusion at a dose of 2 mg/m2 (days 1, 8, and 15; every 4 weeks)
Study: 16551142
Drug: Drug court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug court with usual community services
Study: 16551142
Drug: Drug court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug court with multisystemic therapy
Study: 16551142
Drug: Drug court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug court with multisystemic therapy enhanced with contingency management
Study: 14607573
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) and zinc sulfate (66 mg)
Study: 10892657
Drug: L-arginine (20-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (20-g oral dose)
Study: 8018144
Drug: Dapsone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100 mg twice weekly)
Study: 8018144
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (100 mg every 2 weeks)
Study: 3915459
Drug: Domperidone maleate
Normalized name: domperidone maleate
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone maleate (20 mg t.i.d.)
Study: 29439618
Drug: Prolonged GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged GnRH agonist therapy (3 consecutive IM injections of triptorelin 3.75 mg 28 days apart)